BioRestorative Therapies 주식 (NASDAQ: BRTX)

에 대한 최신 뉴스 BioRestorative Therapies (NASDAQ:BRTX) 주식

BioRestorative Therapies

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies Inc

<a href="https://www.globenewswire.com/Tracker?data=wkDv0HV_VuHdsniKisTeG-jTldVmG5EW_YfNEnzYdOXx8dBAMZ9jWflmEYhVro3txViGAYji6GT-nUJDaDd5bqary_DfX-lMF_nz8JwWXieZt87xu2NvJFOaJhRPnb-YdO69550vykH3B5DTcC2rowaFvElb7LzBuWg6Rx8Siad_TisCAchvfC447b7gTacP20NiraLytvwkOqd4mG0UE_7qI8a7jzRS9oFOkfq-ukED4y3Rj-8a93z-Cfx7kxg7lV7XBw8tIeAWGtYoqW31yqHaPkTEy4jgpcIBpFuZMPXQQ3981xenxMDTw7iW8zgGdnueB-kUQKybCI6HlkLP5FaRnBJOpKyJ46o2jMyq3vpXquDA6Jsn2X7Ac6Ed0fjVteGk1B6NIGxexlPRtDwy2w==">BioRestorative Therapies, Inc</a>. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026.

News

Buybacks

BRTX

BioRestorative Therapies Announces $2M Stock Repurchase Program

WIIM

BioRestorative Therapies shares are trading lower. The company announced the presentation of promising preliminary blinded data from the first 36 subjects in its ongoing Phase 2 clinical trial of BRTX-100.

BioRestorative Reports Preliminary Data For FDA-Fast-Tracked BRTX-100, An Autologous Stem Cell Therapy To Treat Chronic Lumbar Disc Disease; Says Updated Data Presented At ISSCR 2025 Demonstrates >50% Improvement In Pain And Function In Significant Portion Of cLDD Subjects

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced that new preliminary, blinded clinical data from 30 patients enrolled in its ongoing Phase 2 trial of BRTX-100 for the treatment of chronic lumbar disc disease (cLDD) will be presented at the prestigious International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, held June 11–14, 2025, in Hong Kong.
The highly anticipated presentation will be delivered by Francisco Silva, Vice President of Research and Development at BioRestorative, on Friday, June 13, at 5:00 p.m. HKT, as part of ISSCR 2025's clinical innovations track. The Company will issue a press release pre-market that day, detailing the newly reported data.
"This represents a milestone moment for BioRestorative," said Lance Alstodt, Chief Executive Officer. "With preliminary data from twice as many patients as previously shared, we are seeing strong, consistent signals around both safety and functional improvement. We are eager to bring this update to the global scientific community at the world's most influential stem cell conference."
BRTX-100 is BioRestorative's lead clinical candidate — a hypoxic-cultured, autologous mesenchymal stem cell therapy designed to target areas of the body with limited blood flow, such as damaged spinal discs. The ongoing Phase 2 study is a prospective, randomized, double-blinded, placebo-controlled trial evaluating BRTX-100 in patients with cLDD across up to 16 U.S. clinical sites. A total of 99 patients will be enrolled, randomized 2:1 to receive either BRTX-100 or placebo via a single intradiscal injection.
The presentation, titled "Stem Cell Therapy for Chronic Lumbar Disc Disease: Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells," will highlight key preliminary outcomes focused on patient-reported pain and function metrics, as well as safety endpoints.

BioRestorative to Present Stem Cell Trial Data for Back Pain at Global Conference

BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.33) by 93.94 percent. This is a 93.94 percent decrease over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $25.00 thousand which missed the analyst consensus estimate of $380.00 thousand by 93.42 percent. This is a 28.57 percent decrease over sales of $35.00 thousand the same period last year.

Earnings

Earnings Misses

BioRestorative Therapies Q1 EPS $(0.64) Misses $(0.33) Estimate, Sales $25.00K Miss $380.00K Estimate

ADCT

AEVA

AFCG

ALUR

ARCO

ATER

AYTU

BCDA

BITF

BNGO

The Beachbody Company, Inc. Class A Common Stock

BODI

BOOT

BZAI

CAAS

CANG

CCAP

CDXS

CELC

CLBT

CLSD

CREX

CSCO

CSPI

CSWC

CTSO

DAVA

DERM

DRIO

DYAI

EGAN

ELVA

EPSN

EWCZ

FIHL

FOSL

GCTS

GLBE

GROV

GWRS

HWKN

IBTA

ICCC

INVZ

IREN

ISSC

ITRG

JACK

KARO

KITT

KMDA

KRNT

LAZR

LDTC

LIEN

LIQT

LOCL

LUCD

LUXE

LVLU

MDXH

MGRM

MMYT

NEXN

NSYS

NTWK

NVGS

NYXH

ONCY

PDSB

PYPD

RCAT

RDCM

REKR

RELI

RSKD

SBLK

SCPH

SDHC

SDOT

SDST

SGML

SHIM

Earnings Scheduled For May 14, 2025

BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) will release its quarterly earnings report on Wednesday, 2025-05-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate BioRestorative Therapies to report an earnings per share (EPS) of $-0.32.
Anticipation surrounds BioRestorative Therapies's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 1.09% drop in the share price on the subsequent day.
Here's a look at BioRestorative Therapies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.27</td>
<td>-0.43</td>
<td>-0.56</td>
<td>-0.51</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.20</td>
<td>-0.13</td>
<td>-0.50</td>
<td>-0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747159675_0.png" alt="eps graph" />
<h3>Performance of BioRestorative Therapies Shares</h3>
Shares of BioRestorative Therapies were trading at $1.845 as of May 12. Over the last 52-week period, shares are up 23.72%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BRTX/earnings">To track all earnings releases for BioRestorative Therapies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: BioRestorative Therapies's Earnings Preview

<a href="https://www.globenewswire.com/Tracker?data=m86_IPRyJRgdp_Y9V7q4SgFzwddOD8TXjMcognaxk9gA88eQWgY3SWvmb-kkOFMIRKKBI_fiL9gm6KVFUmu_jeqkCyFITbEFzoP_TSwQ9BzTO4VWRTAovWlj_RRmJvJyzqgNe9F6IJhvXy2Mq1hIQYSpEYn5qoWWEffkZxSesAxeVRjD8YD39siciszjqdvijZ9xfUsIRgcpd4piqK95k17790euS92Wo37JOSYbX9W8PUNb-4uBRk9FuZwA_UYiIvBdmzK_hInfhvdvyibp1ht2BNRD0VPpx78hMns5dmwlbxkgRKSa0r2uLrd2Ze9UAqsY72xkWdvMOu9MkuaDXaDtq0b2WtoU499fP9wUfhaOikrLmmXcXiodcxFx0j0Q9BoLSz2U4GmZ-2FFDTEPJQ==">BioRestorative Therapies, Inc</a>. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease ("cLDD") enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell &amp; Gene Therapy ("ISCT") 2025 Annual Meeting.
No serious adverse events (SAEs) were reported, and there was no dose (40X106 cells) limiting toxicity at 26-104 weeks.

BioRestorative Therapies Presents Preliminary Phase 2 BRTX-100 Data At ISCT 2025 Annual Meeting

BioRestorative Therapies Confirms It Faces No Material Impact From Reciprocal Tariffs

BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 64.91 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $43.300 thousand which missed the analyst consensus estimate of $475.000 thousand by 90.88 percent. This is a 124.35 percent increase over sales of $19.300 thousand the same period last year.

Earnings Beats

BioRestorative Therapies Q4 2024 GAAP EPS $(0.20) Beats $(0.28) Estimate, Sales $43.300K Miss $475.000K Estimate

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPG

ABOS

BCAB

BKTI

BKYI

BRFH

BRZE

BTTR

CODX

DLPN

DPRO

DRCT

EDAP

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FORA

FTLF

GEVO

GOVX

ICCM

INMB

IPHA

IRIX

IZEA

JFIN

KULR

LTRN

LULU

MDAI

NUTX

PIII

PLSE

PSTV

RLMD

SACH

SCWO

SKYH

SPRO

SSKN

TLSI

TSAT

TSSI

UMAC

UONE

UONEK

VTSI

WKSP

Earnings Scheduled For March 27, 2025

BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-03-27. Here's a quick overview of what investors should know before the release.
Analysts are estimating that BioRestorative Therapies will report an earnings per share (EPS) of $-0.27.
The market awaits BioRestorative Therapies's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.30 in the last quarter, leading to a 6.1% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2025/1743015722_0.png" alt="eps graph" />
<h3>BioRestorative Therapies Share Price Analysis</h3>
Shares of BioRestorative Therapies were trading at $1.92 as of March 25. Over the last 52-week period, shares are up 29.71%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BRTX/earnings">To track all earnings releases for BioRestorative Therapies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For BioRestorative Therapies

– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting –
– IND clearance expands Company's advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain –
– Company to host webcasted conference call today at 10:30am EST –
MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=t8qE65t7hxTrlrB7iiEgfZp1suOAaDChQQ5iDbLZLC8-cRlF9GaPSrvm4mqkQYeIKp1DP2brqaHVl4b72BKgwhQVRvl5_48Kas6NvizuT43V2XccGZFVK8bFIuo15B4NlQdFGXVQVvS9oSmgNNqZkcQmVIATopVMZBLtBU7H42FabfwZddV_xy6cAxdg13KaOaqF0cP02wC1nD3A6hzYEqn4jvgPE-xl6YVu3ebJf91oOjXsBt1bf0-w_s9ENCGK-OC-OCfmnjtkeqDuPHB37VC_MQnAsvyAX0OIDSI8_fyANUDQmMFxZJo74kvkmamOkNT1rRpCzJeu2mbeTkdbp88g5Ke7CZmHb7BB9eJJ75ObGZ81T2HPxV6IDNPIipSy6-B8SX4019jqhuxIeCnqvA==">BioRestorative Therapies, Inc</a>. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, for the treatment of chronic cervical discogenic pain ("cCDP").

Biotech

General

BioRestorative Announces FDA Clearance Of IND for Phase 2 Trial Of BRTX-100 In Chronic Cervical Discogenic Pain

BioRestorative Says It 'expects to provide a positive clinical pipeline update' Before Market Open Ob Feb. 27 Related To BRTX-100

– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions –
– Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date –
– May also lead to Priority Review and Accelerated Biologics License Application ("BLA") Approval for BRTX-100 –

BioRestorative Receives FDA Fast Track Designation For BRTX-100 Program For Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. Highlights Presentation Or Preliminary BRTX-100 Data At Orthopaedic Research Society

<h3>Gainers</h3>
<ul>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock rose 168.9% to $9.52 during Thursday's pre-market session. The company's market cap stands at $196.3 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock moved upwards by 67.86% to $6.53. The market value of their outstanding shares is at $3.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 30.95% to $3.3. The market value of their outstanding shares is at $2.7 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock increased by 16.43% to $14.81. The company's market cap stands at $673.4 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock increased by 15.0% to $6.9. The company's market cap stands at $143.5 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock increased by 13.38% to $11.0. The market value of their outstanding shares is at $90.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock fell 32.4% to $0.5 during Thursday's pre-market session. The company's market cap stands at $96.8 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock declined by 24.26% to $4.81. The company's market cap stands at $13.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock declined by 12.0% to $1.32. The company's market cap stands at $9.1 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock decreased by 11.91% to $1.85. The market value of their outstanding shares is at $37.4 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) shares decreased by 11.08% to $3.13. The market value of their outstanding shares is at $27.9 million. </li>
<li>Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) stock decreased by 10.5% to $18.0. The company's market cap stands at $4.9 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADVM

BJDX

BLUE

CAPR

Envoy Medical, Inc. - Class A Common Stock

COCH

CRVO

CYCN

MRKR

STVN

TARA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Health Care

BioRestorative Therapies Has Announced That The European Patent Office Has Issued A Notice Of Allowance For A New Patent Application Covering Key Aspects Of The Company's Allogeneic, Off-The-Shelf ThermoStem Metabolic Disease Platform

BioRestorative Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) revealed on Wednesday new preliminary 26 to 52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing <a href="https://www.benzinga.com/pressreleases/24/11/g41934718/biorestorative-therapies-reports-positive-preliminary-phase-2-brtx-100-clinical-data" target="_blank" rel="noreferrer noopener">Phase 2 trial of BRTX-100</a>.
BRTX-100 is a novel cell-based therapeutic engineered to target body areas with little blood flow.
A Phase 2 study is evaluating the safety and efficacy of BRTX-100 in treating cLDD. Up to 99 eligible subjects will be enrolled.
The 10 safety run-in subjects reported no serious adverse events (SAEs).
There was also no dose (40X106 cells) limiting toxicity at 26 to 52 weeks.
The company reported blinded clinical data on the secondary efficacy endpoint of at least a 30% decrease in pain measured on the Visual Analog Scale (VAS) and at least a 30% increase in function based on the Oswestry Disability Index (ODI) at week 52.
The blinded preliminary efficacy endpoint data demonstrated:
<ul>
<li>At 26 weeks, 70% of subjects (n=10) and 100% of subjects (n=4) at 52 weeks reported a &gt;30% improvement in VAS versus baseline.</li>
<li>At 12 and 26 weeks, 70% of subjects (n=10) had a &gt;30% improvement in ODI versus baseline.</li>
<li>At 52 weeks, 100% of subjects (n=4) had a &gt;30% improvement in ODI versus baseline.</li>
<li>At 26 weeks, 70% of subjects (n=10) reported a &gt;30% decrease in pain (VAS)&nbsp;and&nbsp;a &gt;30% increase in function (ODI).</li>
</ul>
BRTX Price Action: BRTX stock is down 1.22% at $1.62 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/24/11/41942999/griffon-surges-ahead-strong-q4-earnings-beat-dividend-hike-buyback-more" target="_blank" rel="noreferrer noopener">Griffon Surges Ahead: Strong Q4 Earnings Beat, Dividend Hike, Buyback &amp; More</a></li>
</ul>
Photo: One Photo via Shutterstock

BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function

BioRestorative Therapies shares are trading higher after the company reported better-than-expected Q3 revenue results. Additionally, the company reported preliminary Phase 2 BRTX-100 clinical data showing a material decrease in pain and increased function.

Press Releases

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

BioRestorative Announces Share Repurchase Program

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

Comments

BioRestorative Therapies

뉴스

에 대한 최신 뉴스 BioRestorative Therapies (NASDAQ:BRTX) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌